ApoB/ApoA‐I Ratio is Associated With Faster Hemodynamic Progression of Aortic Stenosis: Results From the PROGRESSA (Metabolic Determinants of the Progression of Aortic Stenosis) Study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Previous studies reported that middle‐aged patients with atherogenic lipoprotein‐lipid profile exhibit faster progression of aortic valve stenosis ( AS ). The ratio of apolipoprotein B/apolipoprotein A‐I (apoB/apoA‐I) reflects the balance between atherogenic and anti‐atherogenic lipoproteins. The aim of this study was to examine the association between apoB/apoA‐I ratio and AS hemodynamic progression and to determine whether this association varies according to age. Methods and Results: A total of 159 patients (66±13 years, 73% men) with AS were prospectively recruited in the PROGRESSA (Metabolic Determinants of the Progression of Aortic Stenosis) study. Hemodynamic progression of AS was determined by the change in peak aortic jet velocity (V peak ) measured by Doppler‐echocardiography between baseline and 2‐year follow‐up. Patients in the top tertile of apoB/apoA‐I ratio (≥0.62) had a faster progression rate of AS compared with those in the bottom/mid tertiles (V peak progression: 0.30 [0.09˗0.49] versus 0.16 [0.01˗0.36] m/s, P =0.02). There was a significant interaction ( P =0.007) between apoB/apoA‐I ratio and age. Among younger patients (ie, aged <70 years; median value of the cohort), those in the top tertile of apoB/apoA‐I ratio had a 3.4‐fold faster AS progression compared with those in the bottom/mid tertiles (V peak progression: 0.34 [0.13˗0.69] versus 0.10 [−0.03˗0.31] m/s, P =0.002), whereas there was no significant difference between tertiles in the subgroup of older patients ( P =0.83). After comprehensive adjustment, higher apoB/apoA‐I ratio was significantly associated with faster AS progression in the subset of younger patients (all, standardized β≥0.36; P ≤0.01). Conclusions: Higher apoB/apoA‐I ratio is significantly associated with faster hemodynamic progression of AS in the younger patients. These findings suggest that atherogenic lipid factors may play a crucial role in the pathogenesis of AS in younger patients, but may be are less important in older patients. Clinical Trial Registration: URL : https://www.clinicaltrials.gov . Unique identifier: NCT 01679431.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Freeman, R. V., & Otto, C. M. (2005) · Circulation · doi:10.1161/circulationaha.104.486738 · Cited by 1,006
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982
Self-citationRajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O'Brien, K. D., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.006767 · Cited by 842 · cited 12×
“The lack of effect of statins on AS progression in these trials may be explained by: (1) the study populations included predominantly older patients with moderate AS; (2) the benefit of LDL-lowering by statins may have been counterbalanced by some negative effects including increase in insulin resistance and associate…”
BackgroundResultSelf-citationChan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815
Self-citationElevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.020 · Cited by 417
Self-citationArsenault, B. J., Boekholdt, S. M., Dubé, M.-P., Rhéaume, É., Wareham, N. J., Khaw, K.-T., Sandhu, M. S., & Tardif, J.-C. (2014) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000400 · Cited by 315
Self-citationMohty, D., Pibarot, P., Després, J.-P., Côté, C., Arsenault, B., Cartier, A., Cosnay, P., Couture, C., & Mathieu, P. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.154989 · Cited by 181
Self-citationBeyond Low-Density Lipoprotein Cholesterol
Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., & Kwiterovich, P. O. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.045 · Cited by 136
Impact of Metabolic Syndrome on Progression of Aortic Stenosis
Capoulade, R., Clavel, M.-A., Dumesnil, J. G., Chan, K. L., Teo, K. K., Tam, J. W., Côté, N., Mathieu, P., Després, J.-P., & Pibarot, P. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.052 · Cited by 127 · cited 11×
“The lack of effect of statins on AS progression in these trials may be explained by: (1) the study populations included predominantly older patients with moderate AS; (2) the benefit of LDL-lowering by statins may have been counterbalanced by some negative effects including increase in insulin resistance and associate…”
BackgroundResultSelf-citationTastet, L., Capoulade, R., Clavel, M.-A., Larose, É., Shen, M., Dahou, A., Arsenault, M., Mathieu, P., Bédard, É., Dumesnil, J. G., et al. (2017) · European Heart Journal – Cardiovascular Imaging · doi:10.1093/ehjci/jew013 · Cited by 100
Self-citationDerbali, H., Bossé, Y., Côté, N., Pibarot, P., Audet, A., Pépin, A., Arsenault, B., Couture, C., Després, J.-P., & Mathieu, P. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090541 · Cited by 71
Self-citationHekimian, G., Boutten, A., Flamant, M., Duval, X., Dehoux, M., Benessiano, J., Huart, V., Dupré, T., Berjeb, N., Tubach, F., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs450 · Cited by 53
Mohty, D., Pibarot, P., Després, J.-P., Cartier, A., Arsenault, B., Picard, F., & Mathieu, P. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.12.068 · Cited by 53 · cited 2×
“A potential hypothesis to explain this age-related difference is a survival bias.(20,24,25) This hypothesis is supported by a recent sub-analysis of the INTERHEART study, showing an inverse relationship between patient’s age and the risk of myocardial infarction.”
BackgroundResultSelf-citation
Cited by
Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis
Arsenault, B. J., Loganath, K., Girard, A., Botezatu, S., Zheng, K. H., Tzolos, E., Abdoun, K., Tastet, L., Capoulade, R., Côté, N., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.1882 · Cited by 80
Self-citationApoC-III is a novel inducer of calcification in human aortic valves
Schlotter, F., de Freitas, R. C. C., Rogers, M. A., Blaser, M. C., Wu, P.-J., Higashi, H., Halu, A., Iqbal, F., Andraski, A. B., Rodia, C. N., et al. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015700 · Cited by 49
“At the epidemiological level, apoB (7), lp(a) (8, 9), and apoC-III (10, 11) are associated with CAVD, and apoAI has demonstrated an inverse relationship to risk for AS incidence (12) and its hemodynamic progression (13).”
BackgroundResultZheng, K. H., Arsenault, B. J., Kaiser, Y., Khaw, K., Wareham, N. J., Stroes, E. S. G., & Boekholdt, S. M. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013020 · Cited by 32
Self-citationBiomarkers Associated with Aortic Stenosis and Structural Bioprosthesis Dysfunction
Oury, C., Côté, N., & Clavel, M.-A. (2020) · Cardiology Clinics · doi:10.1016/j.ccl.2019.09.005 · Cited by 2
Self-citation
Metadata
- Authors
- Tastet, L., Capoulade, R., Shen, M., Clavel, M., Côté, N., Mathieu, P., Arsenault, M., Bédard, É., Tremblay, A., Samson, M., Bossé, Y., Dumesnil, J. G., Arsenault, B. J., Beaudoin, J., Bernier, M., Després, J., & Pibarot, P.
- Venue
- Journal of the American Heart Association
- Published
- 2018-02-20
- Volume
- 7
- Issue
- 4
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2790231453
- Cited by
- 24
- References
- 18
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.